Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Jeffrey Farrow Sells 2,111 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Jeffrey Farrow sold 2,111 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $69.42, for a total value of $146,545.62. Following the completion of the transaction, the insider owned 47,635 shares of the company’s stock, valued at $3,306,821.70. This trade represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $67.22 on Friday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The stock’s fifty day simple moving average is $69.36 and its 200-day simple moving average is $70.18. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -41.49 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published tighter quarterly and FY‑2026 EPS forecasts (smaller expected losses vs. consensus), which supports a more constructive growth/recovery thesis for the stock. Read More.
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s upgrade improves outlook but does not represent unanimous conviction across all analysts. Read More.
• Neutral Sentiment: Company fundamentals: most recent quarter showed a slight EPS miss (reported ($0.20) vs. ($0.19) estimate) but revenue beat, leaving fundamentals mixed and dependent on future trial/launch catalysts. Read More.
• Neutral Sentiment: High institutional ownership (~90%) is a double‑edged factor — it stabilizes float but means large holders can move the stock if they adjust positions. Read More.
• Negative Sentiment: Significant insider selling disclosed in multiple Form 4s between Mar 16–19: CEO Bobak Azamian sold ~10.9k–12.0k shares across several days (prices ~ $67–$69), director William J. Link sold 12,500 shares (~$68.79), and several other senior officers also reduced stakes — these large, clustered sales can create immediate downward pressure and raise questions about near‑term liquidity needs or portfolio rebalancing. Read More.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Comerica Bank grew its stake in Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after buying an additional 705 shares during the period. Truvestments Capital LLC raised its stake in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after acquiring an additional 468 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after acquiring an additional 172 shares in the last quarter. Osaic Holdings Inc. boosted its position in Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after purchasing an additional 2,462 shares during the period. Finally, Leonteq Securities AG purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth $164,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on TARS. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Mizuho initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective for the company. Finally, Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.